Jefferies Maintains UW Rating On AMAG

Jefferies is maintaining its rating on AMAG Pharmaceuticals (NASDAQ: AMAG).

“We view below-consensus 2011 Feraheme sales guidance as too optimistic and maintain our below-guidance sales estimate,” Jefferies writes. “We remain bearish on Feraheme potential and keep our peak annual sales potential at sub-$100M. With unlikely profitability on Feraheme sales, we maintain Underperform.”

AMAG Pharmaceuticals closed Monday at $16.99.